热门资讯> 正文
ARK Investment buys 560K shares of Intellia Therapeutics
2025-08-19 17:23
- Cathie Wood's ARK Investment has purchased 560,600 shares of biotech and gene editing company Intellia Therapeutics (NASDAQ:NTLA).
- The stock has a Seeking Alpha quant rating of Hold, with the factor grades given to momentum.
- SA Investing Group Leader Edmund Ingham recently upgraded his rating to Buy, citing its lead gene-editing therapies, Lonvo-z and Nex-z, potential with 'one and done' treatment and strong early efficacy and safety data. ''Despite risks, I see NTLA stock as a compelling long-term Buy with triple-digit percentage upside if efficacy and safety are confirmed in late-stage trials." he wrote.
- The stock price traded ~1% higher to $10.83 on Monday during after-market hours of trading.
More on Intellia Therapeutics
- Intellia Therapeutics: It May Be Time To Get Excited And Buy (Upgrade)
- Intellia Therapeutics, Inc. (NTLA) Q2 2025 Earnings Call Transcript
- With Intellia Therapeutics, Human Patience Beat Hot-Take Trading: Still At 'Buy'
- Intellia targets 1,200 patients in expanded Phase III ATTR cardiomyopathy trial as enrollment accelerates
- Intellia Therapeutics Q2 2025 Earnings Preview
推荐文章
美股机会日报 | 凌晨3点！美联储将公布1月货币政策会议纪要，纳指期货涨近0.5%；13F大曝光！巴菲特连续三季减持苹果
美股机会日报 | 阿里发布千问3.5！性能媲美Gemini 3；马斯克称Cybercab将于4月开始生产
港股周报 | 中国大模型“春节档”打响！智谱周涨超138%；巨亏超230亿！美团周内重挫超10%
一周财经日历 | 港美股迎“春节+总统日”双假期！万亿零售巨头沃尔玛将发财报
从软件到房地产，美国多板块陷入AI恐慌抛售潮
Meta计划为智能眼镜添加人脸识别技术
危机四伏，市场却似乎毫不在意
财报前瞻 | 英伟达Q4财报放榜在即！高盛、瑞银预计将大超预期，两大关键催化将带来意外惊喜？
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
